VC
Value Add VC
⚡HomePulse⚡Helpful Apps📝Blog🤝Partner
Illustration for: BOA Acquisition Corp II Files for $200M Blank-Check IPO
Value Add VC/Pulse/IPO$200M target IPO

BOA Acquisition Corp II Files for $200M Blank-Check IPO

BOA Acquisition Corp II filed to raise up to $200 million in a blank-check IPO targeting real estate and infrastructure, part of a steady 2026 revival in SPAC issuance running well below the AI-mega-deal headlines.

By the Numbers

Up to $200 million
Target raise
20M units at $10
Unit structure
Real estate, infrastructure
Target sectors
September 2025
Confidential filing
TC
Trace Cohen
Early-stage VC & angel · Founder, New York Venture Partners
July 9, 2026
2 min read
ShareXLinkedInEmail

THE RUNDOWN

1

BOA Acquisition Corp II, led by CEO Benjamin Friedman and Chairman Brian Friedman, filed to raise up to $200 million through an IPO of 20 million units priced at $10 each, with each unit including one share of common stock and one-eighth of a right to a share upon completing a business combination

2

The SPAC is explicitly targeting real estate and infrastructure opportunities, particularly within energy, telecommunications and transportation -- sectors adjacent to, but distinct from, the AI-model and foundation-lab mega-rounds dominating this week's headlines

3

The filing follows a confidential submission in September 2025, a typical path for SPAC sponsors who want to line up anchor investors before a public registration statement is filed

4

BOA Acquisition Corp II is part of a broader, quieter 2026 revival in SPAC issuance -- new blank-check vehicles have been pricing IPOs at a steady pace this year without the scale or mainstream attention of the 2020-2021 SPAC boom

TC

The VC Read · Trace's Take

Trace Cohen

A well-pedigreed real estate and infrastructure SPAC quietly filing for $200M is exactly the kind of deal that never makes headlines next to Anthropic or Mercor, and that's precisely why it's worth noting -- SPAC issuance is rebuilding real volume in categories nobody's talking about. If you're a real estate or energy infrastructure operator weighing a public listing, this is the quiet path, not the SK Hynix path.

Analysis

BOA Acquisition Corp II, a blank-check company led by CEO, CFO and director Benjamin Friedman and Chairman Brian Friedman, filed with the SEC to raise up to $200 million in an initial public offering, according to filings reviewed by Renaissance Capital and MarketScreener. The structure is a standard SPAC unit offering: 20 million units priced at $10 each, with every unit including one share of common stock and one-eighth of one right to receive an additional share upon completion of a future business combination.

The SPAC's stated focus is real estate and infrastructure, with particular emphasis on energy, telecommunications and transportation assets -- categories tied to, but structurally distinct from, the AI-model and foundation-lab financings dominating this week's larger headlines. Benjamin Friedman's background spans The Avery Companies and Friedman Capital, while Brian Friedman is a partner at Friedman Capital and co-founder of Foxhall Partners, giving the vehicle a real estate and infrastructure-investing pedigree behind its target sectors.

The filing follows a confidential submission in September 2025, the typical path SPAC sponsors take to line up anchor investors and gauge institutional interest before a public registration statement goes live -- a sign of a reasonably conventional, well-advised SPAC process rather than a rushed or opportunistic filing.

BOA Acquisition Corp II's filing is part of a broader, considerably quieter revival in SPAC issuance running through 2026: new blank-check vehicles have been pricing IPOs at a steady pace this year without anywhere near the scale, velocity or mainstream media attention of the 2020-2021 SPAC boom that preceded a wave of poor-performing de-SPAC mergers and tightened SEC disclosure requirements.

For real estate, energy and infrastructure-focused sponsors and targets, BOA Acquisition Corp II's filing is a data point that SPAC capital remains a live option for those specific sectors even as most public-market attention is consumed by AI. For investors, any SPAC vehicle -- however credible its sponsor pedigree -- still carries the structural incentive misalignments that plagued the 2020-2021 cohort, and this generation's sponsors haven't yet proven those issues are structurally resolved.

The bear case: SPACs targeting real estate and infrastructure face their own sector-specific headwinds, including elevated interest rates affecting asset valuations and financing costs for any eventual business combination. What to watch next: whether BOA Acquisition Corp II completes its IPO at the targeted $200 million size, and whether the sponsor identifies and closes a business combination within the SPAC's typical 18-to-24-month deadline.

ShareXLinkedInEmail

More on

BOA Acquisition Corp II →

Reported by Renaissance Capital · Analysis by Value Add Pulse.

← Back to Pulse

THE WIRE in your inbox— Tech, startup & VC news with Trace's take. Free, no spam.

Read Next

IPO· Aug 9, 2026

What BofA's Extreme Bull Signal Means for Your Marks

Illustration for: What BofA's Extreme Bull Signal Means for Your Marks
IPO

What BofA's Extreme Bull Signal Means for Your Marks

BofA's Bull & Bear indicator hit 9.7, its highest since 2021 and above the firm's own 8.0 sell threshold — a trace's-take on what that extreme reading should change about how GPs mark portfolio companies against public comps.

IPO· Aug 8, 2026

Biotech IPOs Are Pricing Above Range Again

Illustration for: Biotech IPOs Are Pricing Above Range Again
IPO$532.5M combined

Biotech IPOs Are Pricing Above Range Again

BlossomHill and Braveheart Bio both upsized and priced above their original ranges this week, the clearest two-deal signal yet that the biotech IPO window -- closed to all but the strongest names in 2024-2025 -- is reopening.

IPO· Aug 7, 2026

BlossomHill Prices Upsized $150M IPO, Debuts on Nasdaq

Illustration for: BlossomHill Prices Upsized $150M IPO, Debuts on Nasdaq
IPO$150M IPO

BlossomHill Prices Upsized $150M IPO, Debuts on Nasdaq

BlossomHill Therapeutics priced an upsized IPO at $16 a share for $150M and began trading on Nasdaq under BLSM, more than 50% above the $100M target Pulse flagged when the company first filed.

@Trace_Cohen·t@nyvp.com